Market Overview

RBC Capital Talks Puma Biotechnology


In a report published Wednesday, RBC Capital Markets analysts maintained an Outperform rating on Puma Biotechnology Inc (NYSE: PBYI), with a price target of $285, saying that neratinib's Phase III ExteNET data were positive and "misread by many in the market following release of the ASCO abstracts two weeks ago."

The full data from Puma's ExteNET Phase III trial testing neratinib in the extended adjuvant breast cancer setting is scheduled to be released in an oral presentation at ASCO on June 1.

In the report RBC Capital Markets noted, "Reaction to the initial data release was negative, but we believe that a few key points were missed and need more careful teasing out: Most investors and oncologists had approximated that the minimum delta between the two trial arms had to be about 3% in order to result in meaningful clinical significance. At face value, the 2.3% DFS difference fell below expectations and the 2.9% DFS-DCIS difference is right at the 3% benchmark."

The company's stock plunged about 25 percent after the abstract release on May 13. The analysts consider the weakness as a "significant buying opportunity," saying that they expect "a few key points to become better appreciated from the ASCO presentation than were initially gathered from the abstract."

Latest Ratings for PBYI

Mar 2019CitigroupMaintainsBuyBuy
Jan 2019Leerink SwannInitiates Coverage OnMarket Perform
Jan 2019GuggenheimDowngradesBuyNeutral

View More Analyst Ratings for PBYI
View the Latest Analyst Ratings

Posted-In: RBC Capital MarketsAnalyst Color Reiteration Analyst Ratings


Related Articles (PBYI)

View Comments and Join the Discussion!

Latest Ratings

PEPMorgan StanleyReiterates137.0
AZRXH.C. WainwrightMaintains7.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

Benzinga's Top #PreMarket Gainers

Brown Shoe Posts Upbeat Q1 Results, Lifts Earnings Forecast